Abstract
In recent years, several therapeutic advances have been made in squamous cell carcinoma of the head and neck (SCCHN). However, despite multimodality therapy, patients with locally advanced SCCHN continue to demonstrate suboptimal 5-year survival rates. The addition of novel, targeted agents to traditional therapies holds promise for clinical benefit. This review will focus on new agents that are promising and their potential role in the treatment of SCCHN.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 611-619 |
| Number of pages | 9 |
| Journal | Clinical Advances in Hematology and Oncology |
| Volume | 4 |
| Issue number | 8 |
| State | Published - Aug 2006 |
| Externally published | Yes |
Fingerprint
Keywords
- COX-2
- EGFR
- Head and neck cancer
- Sorafenib
- VEGF
ASJC Scopus subject areas
- Oncology
- Hematology
Cite this
Emerging molecular targeted therapies in squamous cell carcinoma of the head and neck. / Gilbert, Jill; Argiris, Athanassios.
In: Clinical Advances in Hematology and Oncology, Vol. 4, No. 8, 08.2006, p. 611-619.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Emerging molecular targeted therapies in squamous cell carcinoma of the head and neck
AU - Gilbert, Jill
AU - Argiris, Athanassios
PY - 2006/8
Y1 - 2006/8
N2 - In recent years, several therapeutic advances have been made in squamous cell carcinoma of the head and neck (SCCHN). However, despite multimodality therapy, patients with locally advanced SCCHN continue to demonstrate suboptimal 5-year survival rates. The addition of novel, targeted agents to traditional therapies holds promise for clinical benefit. This review will focus on new agents that are promising and their potential role in the treatment of SCCHN.
AB - In recent years, several therapeutic advances have been made in squamous cell carcinoma of the head and neck (SCCHN). However, despite multimodality therapy, patients with locally advanced SCCHN continue to demonstrate suboptimal 5-year survival rates. The addition of novel, targeted agents to traditional therapies holds promise for clinical benefit. This review will focus on new agents that are promising and their potential role in the treatment of SCCHN.
KW - COX-2
KW - EGFR
KW - Head and neck cancer
KW - Sorafenib
KW - VEGF
UR - http://www.scopus.com/inward/record.url?scp=33748983981&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748983981&partnerID=8YFLogxK
M3 - Article
C2 - 17099619
AN - SCOPUS:33748983981
VL - 4
SP - 611
EP - 619
JO - Clinical advances in hematology & oncology : H&O
JF - Clinical advances in hematology & oncology : H&O
SN - 1543-0790
IS - 8
ER -